Reviewing Eloxx Pharmaceuticals (NASDAQ:ELOX) and Cyclo Therapeutics (NASDAQ:CYTH)

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Cyclo Therapeutics (NASDAQ:CYTH) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, dividends and analyst recommendations.

Earnings & Valuation

This table compares Eloxx Pharmaceuticals and Cyclo Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eloxx Pharmaceuticals	N/A	N/A	-$36.06 million	($9.07)	N/A
Cyclo Therapeutics	$1.13 million	17.71	-$20.06 million	($0.90)	-0.78

Cyclo Therapeutics has higher revenue and earnings than Eloxx Pharmaceuticals. Cyclo Therapeutics is trading at a lower price-to-earnings ratio than Eloxx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations for Eloxx Pharmaceuticals and Cyclo Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	0	0	0	0	0.00
Cyclo Therapeutics	0	2	1	0	2.33

Cyclo Therapeutics has a consensus price target of $0.95, indicating a potential upside of 35.91%. Given Cyclo Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Cyclo Therapeutics is more favorable than Eloxx Pharmaceuticals.

Profitability

This table compares Eloxx Pharmaceuticals and Cyclo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Cyclo Therapeutics	-1,830.27%	-2,741.89%	-269.95%

Insider and Institutional Ownership

2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. Comparatively, 68.6% of Cyclo Therapeutics shares are owned by institutional investors. 20.2% of Eloxx Pharmaceuticals shares are owned by company insiders. Comparatively, 29.8% of Cyclo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Eloxx Pharmaceuticals has a beta of 2.63, indicating that its share price is 163% more volatile than the S&P 500. Comparatively, Cyclo Therapeutics has a beta of -0.38, indicating that its share price is 138% less volatile than the S&P 500.

Summary

Cyclo Therapeutics beats Eloxx Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.